Sequence-dependent Antiproliferative Effects of Cetuximab and Cytotoxic Drugs to HepG2 and Bel-7402 Cells

韦玮,郭荣平,李锦清,徐立,张亚奇
DOI: https://doi.org/10.3321/j.issn:1672-3554.2008.05.012
2008-01-01
Abstract:【Objective】 To evaluate the inhibition effects of cetuximab on proliferation of HepG2 and Bel-7402 cells in different sequences of combination with either epirubicin,oxaliplatin, paclitaxel or irinotecan, explore the optimal treatment schedule of combination of cetuximab and cytotoxic drugs. 【Methods】 Increasing concentrations of cetuximab(5~500 mg / mL)combined respectively with epirubicin(0.025~2.5 μmol / L), oxaliplatin(0.5~50 μmol / L), paclitaxel(0.001~0.1 μmol / L) or irinotecan (0.05~5 μmol / L) were administrated to HCC cell lines HepG2 and Bel-7402 with different sequences, the proliferation inhibition effects on HepG2 and Bel-7402 cells were detected with CCK-8 assay, the IC50 and CI of cetuximab and either of cytotoxic drug were calculated. 【Results】 The combination of a cytotoxic drug with cetuximab caused different antiproliferative effects on HepG2 and Bel-7402 cells depending on different treatment sequences. The respective IC50 of cetuximab and cytotoxic drugs decreased when cetuximab followed by chemotherapy, while the CI values were all 1, which indicated an antagonistic interaction. In contrast, when chemotherapy was followed by cetuximab, the respective IC50 of drugs decreased more remarkably and the CI values were all 1,which indicated a significant synergistic antiproliferative activity. 【Conclusions】 The combination of cetuximab and cytotoxic drugs can increase the antiproliferative effects on HepG2 and Bel-7402 cells. The optimal treatment sequence is chemotherapy followed by cetuximab, it can obtain obvious synergistic activity and conduce to less doses and milder side effects in clinical application.
What problem does this paper attempt to address?